Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced two poster presentations at the 18th NFXF International Fragile X Conference, being held July 14-17, 2022, in San Diego, Calif. In addition, Zynerba management will present a company presentation during the conference’s Keynote – Industry Updates session. Copies of the presentation and posters will be made available on the Zynerba corporate website following the presentations at www.zynerba.com/publications.
Corporate Presentation Details
| Title: | Zynerba Pharmaceuticals – Development of ZYN002 (Zygel™) for the Treatment of Behavioral Symptoms in Fragile X Syndrome: Partnering to advance the care of children and adolescents with Fragile X Syndrome |
| Date: | Friday, July 15, 2022 |
| Time: | 3:15 p.m. – 4:30 p.m. PT (6:15 – 7:30 p.m. ET) |
| Location: | Town and Country – A, Town and Country Resort, San Diego, Calif. |
Poster Presentation Details
| Title: | Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel
in Children and Adolescents With Fragile X Syndrome (ZYN2-CL-017) |
| Title: | RECONNECT (ZYN2-CL-033): Design of a Phase 3 Trial of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Fragile X Syndrome Based Upon Learnings From CONNECT-FX (ZYN2-CL-016) |
| Date: | Friday, July 15, 2022 |
| Time: | 4:30 p.m. – 7:00 p.m. PT (7:30 – 10:30 p.m. ET) |
| Location: | Town and Country Foyer, Town and Country Resort, San Diego, Calif. |
-260x195.jpeg)
